OUTLOOK THERAPEUTICS company info

What does OUTLOOK THERAPEUTICS do?
Outlook Therapeutics (NASDAQ:OTLK) specializes in developing and delivering innovative treatments for ocular diseases. Focused primarily on advancing ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for use in retinal indications, the company aims to address the critical needs of patients with eye diseases through rigorous research and targeted therapies. Their objective is not only to provide new, more accessible options for those suffering from conditions like wet age-related macular degeneration (wet AMD) but also to improve upon the safety and efficacy profiles of existing treatments. Engaged in clinical trials and regulatory processes, Outlook Therapeutics is committed to making a meaningful difference in the field of ophthalmology.
OUTLOOK THERAPEUTICS company media
Company Snapshot

Is OUTLOOK THERAPEUTICS a public or private company?

key
Ownership
Public

How many people does OUTLOOK THERAPEUTICS employ?

people
Employees
24

What sector is OUTLOOK THERAPEUTICS in?

pie chart
Sector
Health Care

Where is the head office for OUTLOOK THERAPEUTICS?

location pin
Head Office
New Jersey, United States

What year was OUTLOOK THERAPEUTICS founded?

founded flag
Year Founded
2010
What does OUTLOOK THERAPEUTICS specialise in?
/Ophthalmic Therapies /Bio-pharmaceutical Development /Lytenava Research /Wet AMD Treatment /Retinal Diseases /Clinical Trials

What are the products and/or services of OUTLOOK THERAPEUTICS?

Overview of OUTLOOK THERAPEUTICS offerings
Development of ONS-5010 / LYTENAVA (bevacizumab-vikg), a proposed biosimilar to Avastin, aimed at treating wet age-related macular degeneration and other retinal diseases.
Clinical trials for the efficacy and safety of ONS-5010 / LYTENAVA in treating branch retinal vein occlusion (BRVO), a significant cause of vision loss.
Research into the use of ONS-5010 / LYTENAVA for treating diabetic macular edema (DME), focusing on improving vision and retinal health in diabetics.
Preparation and submission of a Biologics License Application (BLA) to the FDA for ONS-5010 / LYTENAVA, targeting regulatory approval for commercialization.
Partnership initiatives for the global commercialization of ONS-5010 / LYTENAVA, aiming to make the treatment available worldwide.
Ongoing post-marketing studies to assure long-term efficacy and safety of their biosimilar products, ensuring patient safety and compliance with regulatory standards.

Who is in the executive team of OUTLOOK THERAPEUTICS?

OUTLOOK THERAPEUTICS leadership team
  • Mr. Ralph H. Thurman
    Mr. Ralph H. Thurman
    Independent Executive Chairman
  • Mr. C. Russell Trenary III
    Mr. C. Russell Trenary III
    President, CEO & Director
  • Mr. Lawrence A. Kenyon CPA
    Mr. Lawrence A. Kenyon CPA
    Executive VP, CFO, Treasurer, Company Secretary & Director
  • Mr. Jeffrey  Evanson
    Mr. Jeffrey Evanson
    Chief Commercial Officer
  • Ms. Alicia  Tozier
    Ms. Alicia Tozier
    Senior Vice President, Marketing & Market Access
  • Mr. Joel  Prieve
    Mr. Joel Prieve
    Senior Vice President of Licensing and M&A
  • Dr. Surendra  Sharma M.D.
    Dr. Surendra Sharma M.D.
    Senior Vice President of Medical Affairs
  • Dr. Jennifer M. Kissner Ph.D.
    Dr. Jennifer M. Kissner Ph.D.
    Senior Vice President of Clinical Development & Regulatory Affairs